Arsenal Biosciences
Next-generation CAR-T

Arsenal’s novel approach can directly edit the genome of a patient’s impaired immune system cells in vitro with an automatable process that increases the breadth, accuracy, and complexity of value-added genome edits (e.g., added potency, resistance to tumor evasion, increased tumor killing, reduction in toxicity) while dramatically reducing the current standards for COGS and CAPEX, and potentially the reverse logistics of central manufacturing. Arsenal’s core technology is a proprietary non-viral DNA delivery process, exclusively licensed from UCSF, exhibiting a capacity to deliver rising amounts of DNA into human cells at declining cost per kilobase.

Dana-Farber Cancer Institute
UC San Francisco
University of Pennsylvania
Life Science
Initial Investment Stage
View Website